<DOC>
	<DOCNO>NCT02073916</DOCNO>
	<brief_summary>This open-label , single-center study ass safety tolerability combine trastuzumab emtansine ( T-DM1 ) Lapatinib Abraxane patient metastatic HER2-positive breast cancer . Patients receive Abraxane Day 1 1-week cycle T-DM1 Day 1 3-week cycle . Patients take Lapatinib orally daily . Anticipated time study treatment 12 week patient metastatic breast cancer , disease progression unacceptable toxicity occur . Subjects may continue treatment past 12 week respond study treatment . The purpose study test safety Trastuzumab Emtansine combination Abraxane Lapatinib different dose level . The investigator propose phase Ib study ass maximum tolerate dose ( MTD ) Trastuzumab Emtansine combination Lapatinib plus Abraxane metastatic Her2 over-expressed breast cancer . The investigator hypothesize combine antibody-drug conjugate trastuzumab-emtansine lapatinib together Abraxane improve clinical efficacy affect PI3K ERK1,2 MAPK pathway .</brief_summary>
	<brief_title>TDM1 With Abraxane Lapatinib Metastatic HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Documented metastatic Her2 overexpressed breast cancer . Age ≥ 18 year Patients must receive least two prior therapy malignant disease . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) Adequate organ function ( cardiac ejection fraction ≥ 45 % ) , CBC le .75 institutional low limit . Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 2.5 X upper limit normal , unless bone metastasis present absence liver metastasis Bilirubin &lt; 1.5 mg/dL Patients must adequate renal function : creatinine &lt; 1.5 mg/dL recommend ; however , institutional norm acceptable . Negative serum urine βhCG pregnancy test screening patient childbearing potential Fertile patient must use effective contraception ( barrier method condom , diaphragm also conjunction spermicidal jelly , total abstinence . Oral , injectable , implant hormonal contraceptive allow ) . Contraception method must use treatment three month complete treatment Signed informed consent form ( ICF ) Any medical psychiatric condition would prevent informed consent limit survival le 4 week . Absolute QT interval &gt; 460 msec presence potassium &gt; 4.0mEq/L Magnesium &gt; 1.8mg/dl . Patient HIV post transplant associate lymphoproliferative disorder . Patient concurrent use complementary alternative medicine would confound interpretation toxicity antitumor activity Trastuzumab Emtansine , Lapatinib Abraxane . Pregnant lactate woman . Concurrent treatment investigational agent participation another therapeutic clinical trial Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate trastuzumab Emtansine , lapatinib , abraxane , component . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Subjects ulcerative colitis also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 positive Breast Cancer</keyword>
</DOC>